Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group

Since late 2020, a rare prothrombotic thrombocytopenic condition has been observed to arise within 5 to 30  days after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. This condition – called “Vaccine Induced Immune Thrombotic Thrombocytopenia” (VITT) – has many similarities to an atypical variant of heparin-induced thrombocytopenia, including unusual sites for VTE, in addition to positive platelet-activating antibodies against platelet factor 4 (PF4) [2]. Prior to SARS-CoV-2, “spontaneous HIT” was described in the absence of proximate exposure to heparin [3].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research

Related Links:

Semin Thromb Hemost DOI: 10.1055/s-0041-1736168Despite the huge efforts globally underway for preventing or limiting the spread of severe acute respiratory coronavirus disease 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic outbreak appears still virtually unstoppable. As for many other infectious diseases, COVID-19 vaccination has now become crucial for limiting viral spread, especially for averting hospitalizations, need for intensive care, and fatal outcome. Nonetheless, as for other vaccines, COVID-19 vaccination is not completely free from side effects. Among the adverse events that have been reported...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Vaccination is an effective strategy to reduce the burden of the coronavirus disease 2019 (COVID-19) pandemic. A number of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved and proven highly effective, without a counterbalancing safety signal in randomized trials [1 –4].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Acta Haematol. 2021 Oct 6:1-4. doi: 10.1159/000519451. Online ahead of print.ABSTRACTVaccine-induced immune thrombotic thrombocytopenia (VITT) has already been described after vaccination with ChAdOx2 nCov-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson/Janssen). However, less knowledge so far has been gained about optimal therapeutic regimens in VITT-suspected patients. Here, we report the case of a 26-year-old female patient, who developed bilateral deep vein thrombosis in the lower legs and severe thrombocytopenia after ChAdOx2 nCov-19 vaccination. After initial anticoagulation therapy regimens including fondapa...
Source: Acta Haematologica - Category: Hematology Authors: Source Type: research
Recently, heparin-induced thrombocytopenia (HIT) after vaccination with the vaccines manufactured by AstraZeneca and Pfizer –BioNTech has been published in the New England Journal of Medicine. These reports state ...
Source: Thrombosis Journal - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
We report clinical, laboratory, imaging findings and treatment in a 51-year-old female presenting with acute left middle cerebral artery (MCA) occlusion 7 days after the first dose of ChAdOx1 nCoV-19 vaccine.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Tags: Short Communication Source Type: research
J Korean Med Sci. 2021 Aug 9;36(31):e223. doi: 10.3346/jkms.2021.36.e223.ABSTRACTVaccination with an adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can result in the rare development of thrombosis with thrombocytopenia mediated by platelet-activating antibodies against platelet factor 4 (PF4). This is a life-threating condition that may be accompanied by bleeding due to thrombocytopenia with thrombosis of the cerebral venous sinus or splanchnic vein. Herein, we describe the first fatal case of thrombosis with thrombocytopenia syndrome in Korea, presenting with intracranial he...
Source: J Korean Med Sci - Category: General Medicine Authors: Source Type: research
More News: Coronavirus | COVID-19 | Hematology | Respiratory Medicine | SARS | Thrombocytopenia | Thrombosis | Vaccines